Silvia Novello

20PUBLICATIONS
250CO-AUTHORS
Molecular targetsCancer geneticsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

|Sep 10, 2025
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?

Riziero Esposito Abate, Alessandro Morabito, Michele Milella

|Oct 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.

Filippo G Dall'Olio, Wael Zrafi, Veronique Roelants

|Jun 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim

|Dec 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.

Francesco Passiglia, Luisella Righi, Paolo Bironzo

Pageof 4

Frequent Collaborators

5 joint publications

Giorgio Vittorio Scagliotti

4 joint publications

Paolo Bironzo

3 joint publications

Annapaola Mariniello

3 joint publications

Luisella Righi